Peter WT Pisters, M.D., begins tenure as MD Anderson president
MD Anderson Cancer Center welcomes Peter WT Pisters, M.D., as the 76-year-old institution’s fifth full-time president. Pisters was...
Six MD Anderson researchers chosen for AAAS
In recognition of their contributions to basic, translational, and clinical research, six faculty members from MD Anderson Cancer...
Chronic stress may promote resistance to lung cancer therapy
Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly...
Addition of ribociclib improves survival...
The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (PFS) in pre-menopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at MD Anderson.
The trial results, presented at the 2017 San Antonio Breast Cancer Symposium by...
Study shows PARP inhibitor’s benefit for advanced breast...
In a randomized, Phase III trial led by MD Anderson researchers, the PARP inhibitor talazoparib extended progression-free survival...
Advances in blood cancer treatment presented at ASH meeting
Researchers from MD Anderson Cancer Center presented their latest findings involving drug treatments for blood cancers at the...